Adalimumab for nail psoriasis: Efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial
Journal of the European Academy of Dermatology and Venereology | Oct 09, 2019
Secukinumab is effective in treatment of moderate to severe plaque psoriasis: Real-life effectiveness and safety from the PROSPECT study
Journal of the European Academy of Dermatology and Venereology | Sep 29, 2019
Age and gender influence on HIDRAdisk outcomes in adalimumab-treated hidradenitis suppurativa patients
Journal of the European Academy of Dermatology and Venereology | Sep 26, 2019
Most read this week